Schellenberg Wittmer acted as co-counsel for Sosei Heptares on its acquisition of Idorsia Pharmaceuticals Ltd’s pharmaceuticals business in Japan and APAC.
Sosei Group acquired all shares of Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd. The Transaction also included the assignment of the license on the lead product PIVLAZ® (clazosentan), and all territorial related intellectual property and know-how, as well as license rights to daridorexant for Japan and APAC.
The team of Schellenberg Wittmer consisted of Lorenza Ferrari Hofer (IP / Life Sciences), Tarek Houdrouge (M&A / Capital Markets), Olivier Hari (Lead M&A / Capital Markets), Alexander Zundel (M&A / Capital Markets), Jean-Frédéric Maraia (Taxation), Helen Reinhardt (IP / Life Sciences), and Gian Berner (Trainee Lawyer).